vs
艾伯维（ARGX）与Krystal Biotech, Inc.（KRYS）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Krystal Biotech, Inc.的23.1倍（$2.5B vs $107.1M）。Krystal Biotech, Inc.净利率更高（48.0% vs 35.5%，领先12.5%）。艾伯维同比增速更快（83.2% vs 17.5%）。艾伯维自由现金流更多（$322.4M vs $75.4M）
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
ARGX vs KRYS — 直观对比
营收规模更大
ARGX
是对方的23.1倍
$107.1M
营收增速更快
ARGX
高出65.7%
17.5%
净利率更高
KRYS
高出12.5%
35.5%
自由现金流更多
ARGX
多$247.0M
$75.4M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $107.1M |
| 净利润 | $877.2M | $51.4M |
| 毛利率 | 89.5% | — |
| 营业利润率 | 28.9% | 41.5% |
| 净利率 | 35.5% | 48.0% |
| 营收同比 | 83.2% | 17.5% |
| 净利润同比 | 1.3% | 13.0% |
| 每股收益（稀释后） | $13.25 | $1.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARGXKRYS
| Q4 25 | $2.5B | $107.1M | ||
| Q3 25 | — | $97.8M | ||
| Q2 25 | $1.8B | $96.0M | ||
| Q1 25 | — | $88.2M | ||
| Q4 24 | $1.4B | $91.1M | ||
| Q3 24 | — | $83.8M | ||
| Q2 24 | $901.9M | $70.3M | ||
| Q1 24 | — | $45.3M |
净利润ARGXKRYS
| Q4 25 | $877.2M | $51.4M | ||
| Q3 25 | — | $79.4M | ||
| Q2 25 | $414.8M | $38.3M | ||
| Q1 25 | — | $35.7M | ||
| Q4 24 | $865.6M | $45.5M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | $-32.5M | $15.6M | ||
| Q1 24 | — | $932.0K |
毛利率ARGXKRYS
| Q4 25 | 89.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 90.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 89.4% | — | ||
| Q1 24 | — | — |
营业利润率ARGXKRYS
| Q4 25 | 28.9% | 41.5% | ||
| Q3 25 | — | 42.3% | ||
| Q2 25 | 19.2% | 40.9% | ||
| Q1 25 | — | 41.0% | ||
| Q4 24 | 8.7% | 45.4% | ||
| Q3 24 | — | 26.8% | ||
| Q2 24 | -15.4% | 12.2% | ||
| Q1 24 | — | -14.8% |
净利率ARGXKRYS
| Q4 25 | 35.5% | 48.0% | ||
| Q3 25 | — | 81.2% | ||
| Q2 25 | 23.4% | 39.9% | ||
| Q1 25 | — | 40.5% | ||
| Q4 24 | 64.1% | 49.9% | ||
| Q3 24 | — | 32.4% | ||
| Q2 24 | -3.6% | 22.2% | ||
| Q1 24 | — | 2.1% |
每股收益（稀释后）ARGXKRYS
| Q4 25 | $13.25 | $1.69 | ||
| Q3 25 | — | $2.66 | ||
| Q2 25 | $6.32 | $1.29 | ||
| Q1 25 | — | $1.20 | ||
| Q4 24 | $13.33 | $1.53 | ||
| Q3 24 | — | $0.91 | ||
| Q2 24 | $-0.55 | $0.53 | ||
| Q1 24 | — | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5B | $496.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $1.2B |
| 总资产 | $8.7B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARGXKRYS
| Q4 25 | $3.5B | $496.3M | ||
| Q3 25 | — | $392.6M | ||
| Q2 25 | $2.1B | $353.8M | ||
| Q1 25 | — | $308.8M | ||
| Q4 24 | $1.5B | $344.9M | ||
| Q3 24 | — | $374.0M | ||
| Q2 24 | $1.4B | $345.8M | ||
| Q1 24 | — | $359.0M |
总债务ARGXKRYS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $11.0M | — | ||
| Q1 24 | — | — |
股东权益ARGXKRYS
| Q4 25 | $7.3B | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $6.1B | $1.0B | ||
| Q1 25 | — | $984.7M | ||
| Q4 24 | $5.5B | $946.4M | ||
| Q3 24 | — | $885.8M | ||
| Q2 24 | $4.3B | $838.9M | ||
| Q1 24 | — | $799.2M |
总资产ARGXKRYS
| Q4 25 | $8.7B | $1.3B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $7.2B | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $6.2B | $1.1B | ||
| Q3 24 | — | $982.3M | ||
| Q2 24 | $4.8B | $917.7M | ||
| Q1 24 | — | $853.3M |
负债/权益比ARGXKRYS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $323.3M | $77.5M |
| 自由现金流经营现金流 - 资本支出 | $322.4M | $75.4M |
| 自由现金流率自由现金流/营收 | 13.0% | 70.4% |
| 资本支出强度资本支出/营收 | 0.0% | 2.0% |
| 现金转化率经营现金流/净利润 | 0.37× | 1.51× |
| 过去12个月自由现金流最近4个季度 | $594.5M | $188.9M |
8季度趋势，按日历期对齐
经营现金流ARGXKRYS
| Q4 25 | $323.3M | $77.5M | ||
| Q3 25 | — | $39.7M | ||
| Q2 25 | $361.8M | $52.7M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | $41.9M | $52.8M | ||
| Q3 24 | — | $58.9M | ||
| Q2 24 | $-124.7M | $-4.2M | ||
| Q1 24 | — | $15.9M |
自由现金流ARGXKRYS
| Q4 25 | $322.4M | $75.4M | ||
| Q3 25 | — | $38.0M | ||
| Q2 25 | $356.6M | $50.8M | ||
| Q1 25 | — | $24.8M | ||
| Q4 24 | $40.9M | $52.0M | ||
| Q3 24 | — | $57.8M | ||
| Q2 24 | $-125.5M | $-5.3M | ||
| Q1 24 | — | $14.6M |
自由现金流率ARGXKRYS
| Q4 25 | 13.0% | 70.4% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | 20.1% | 52.9% | ||
| Q1 25 | — | 28.1% | ||
| Q4 24 | 3.0% | 57.1% | ||
| Q3 24 | — | 69.0% | ||
| Q2 24 | -13.9% | -7.5% | ||
| Q1 24 | — | 32.3% |
资本支出强度ARGXKRYS
| Q4 25 | 0.0% | 2.0% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 0.3% | 2.0% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | 0.1% | 0.9% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | 0.1% | 1.6% | ||
| Q1 24 | — | 2.8% |
现金转化率ARGXKRYS
| Q4 25 | 0.37× | 1.51× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | 0.87× | 1.38× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | 0.05× | 1.16× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | -0.27× | ||
| Q1 24 | — | 17.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
